AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Apr 25, 2018 at 11:32 AM.

  1. #1 cafead, Apr 25, 2018 at 11:32 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,979
    Likes Received:
    3
    via
    • In the SELECT-SUNRISE study, upadacitinib met the primary endpoint of ACR20 (An ACR20 score means that a person's RA has improved by 20%) across all doses (7.5 mg, 15 mg, 30 mg, once-daily) at week 12, with a significant difference in ACR20 compared to placebo observed as early as week one
    • Significantly more patients receiving upadacitinib achieved ACR50, ACR70 and clinical remission at week 12 compared to placebo

    article source
     
    Quote

Reply to Thread